Comparison Between Standard and Reduced Doses of Indocyanine Green in Fluorescence Cholangiography During Laparoscopic Cholecystectomy.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Intravenous injection of indocianine green at least three hours before surgery at a dose of 2.5 mg per subject., Intravenous injection of indocianine green 15 to 30 minutes before surgery at a dose of 0.25 mg per subject..
- Who it may be relevant to
- Registry conditions: Laparoscopic Cholecystectomy Surgery. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Reduced Dose vs Standard Dose of Indocyanine Green in Near-infrared Fluorescence Cholangiography During Laparoscopic Cholecystectomy: a Randomized Clinical Trial.
Overview
Introduction: This protocol outlines a randomized phase IV clinical trial designed to compare the efficacy of two different doses of indocyanine green (ICG) used in near-infrared fluorescent cholangiography during laparoscopic cholecystectomy (LC)-the current gold standard treatment for symptomatic cholelithiasis. Despite its effectiveness, LC is still associated with significant risks, particularly bile duct injury (BDI), a severe complication that this study aims to mitigate. Phase: Phase IV Study design: Multicenter, randomized, open-label, parallel-group clinical trial (modified intention-to-treat). Objectives: Primary objective: * To analyze differences between treatment groups (standard dose 2.5 mg \>3h preoperative vs reduced dose 0.25 mg immediate preoperative 15-30 min) during laparoscopic cholecystectomy in: * Visualization of extrahepatic biliary structures * Degree of visualization * Degree of background liver fluorescence interference * Perceived utility of the technique Secondary objectives: * Influence of BMI, biliary pathology type, surgery type, prior inflammation, surgical difficulty, previous instrumentation, and laparoscopic imaging system on results * Intraoperative and postoperative complication rates * 30-day mortality * Impact on operative time and hospital stay * Correlation between subjective and objective fluorescence assessment (ducts-to-liver fluorescence ratio) Population: Patients ≥18 years indicated for laparoscopic cholecystectomy (elective, early or urgent deferred). Main inclusion criteria: * Age ≥18 years * Signed informed consent * Indication for laparoscopic cholecystectomy (symptomatic cholelithiasis, gallbladder polyps with surgical indication) Main exclusion criteria: * Age \<18 years * Pregnancy or lactation * Chronic kidney disease (stage \>IIIb) * ICG or iodinated contrast allergy * Functional thyroid disease * Emergency non-deferrable surgery * Open approach * Suspicion of gallbladder carcinoma * Inability to understand the study Investigational product: Indocyanine green (ICG), intravenous administration This multicenter study involves two hospitals in Castilla y León, Spain, and plans to enroll 122 adult patients meeting specific clinical criteria for LC. Participants will be randomized into two treatment arms and will receive ICG accordingly: * Group 1: 2.5 mg \>3h before surgery * Group 2: 0.25 mg 15-30 min before surgery Fluorescence will be assessed both subjectively by the surgical team and objectively through digital image analysis using specialized software to calculate the bile duct-to-liver fluorescence ratio (RFBH). Endpoints: * Rates and degree of biliary structure identification pre- and post-dissection * Perceived utility of cholangiography * Liver background fluorescence interference * Ducts-to-liver fluorescence ratio Duration: 12 months recruitment + 1 month follow-up = total 13 months Countries: Spain Ethics: The study will be conducted in accordance with ICH-GCP, EU Clinical Trials Regulation No 536/2014, and applicable national regulations. Beyond comparing the diagnostic performance of two dosing strategies, this study seeks to provide evidence supporting a more practical and logistically feasible approach for implementing ICG fluorescence cholangiography in routine surgical practice, without compromising diagnostic accuracy or patient safety.
Interventions
- Drug Intravenous injection of indocianine green at least three hours before surgery at a dose of 2.5 mg per subject.
A dilution will be prepared by dissolving 25 mg of ICG in 10 mL of water for injectable solutions, yielding a concentration of 2.5 mg/mL. Once the solution is prepared, 1 mL will be administered directly via a peripheral venous line in the patient's upper limb. - Drug Intravenous injection of indocianine green 15 to 30 minutes before surgery at a dose of 0.25 mg per subject.
A dilution will be prepared by dissolving 25 mg of ICG in 25 mL of water for injectable solutions, yielding a concentration of 1 mg/mL. Subsequently, 0.25 mL will be administered as a direct intravenous injection via a peripheral venous line in the patient's upper limb.
Primary outcome measures
- Identification of biliary structures prior to dissection of the hepatocystic triangle. [Time frame: During surgery]
- Identification rate of biliary structures after dissection of the hepatocystic triangle [Time frame: During surgery.]
- Degree of identification of extrahepatic biliary structures prior to dissection of the hepatocystic triangle [Time frame: During surgery]
- Degree of identification of extrahepatic biliary structures after dissection of the hepatocystic triangle [Time frame: During surgery.]
- Perceived usefulness of fluorescence cholangiography (FC). [Time frame: During surgery]
- Degree to which background liver fluorescence (contrast between the liver and biliary ducts) was perceived as disturbing [Time frame: During surgery]
Secondary outcome measures (4)
- To analyze the rate of postoperative complications related to FC during LC. [Time frame: From surgery to 30 days post-surgery]
- To analyze hospital and 30-day mortality rates. [Time frame: From surgery to 30 days post-surgery]
- To analyze the impact of the technique on operative time, intraoperative/postoperative complications, and hospital stay. [Time frame: From surgery to 30 days post-surgery.]
- To analyze the correlation between the subjective and objective assessment of the procedure through the use of the bile duct-to-liver fluorescence ratio. [Time frame: During surgery.]
Eligibility criteria
Inclusion criteria
- Age ≥18 years.
- Signed informed consent.
- Indication for laparoscopic cholecystectomy (symptomatic cholelithiasis or gallbladder polyps).
Exclusion criteria
- Age <18 years.
- Pregnancy or lactation.
- Chronic kidney disease (stage >IIIb).
- ICG allergy.
- Allergy to other iodinated contrast
- Functional thyroid disease.
- Emergency non-deferrable surgery.
- Open approach.
- Suspicion of gallbladder cancer.
- Inability to understand the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Spain · 2 centers
- Hospital Universitario de Salamanca — Salamanca
- Hospital Virgen de la Concha — Zamora
Identifiers
NCT: NCT07195331 · Low-DOTIG · 2025-522535-33-00